VEGFR endocytosis: Implications for angiogenesis

Saikia, Queen; Reeve, Hannah; Alzahrani, Areej; Critchley, William R.; Zeqiraj, Elton; Divan, Aysha; Harrison, Michael A.; Ponnambalam, Sreenivasan

doi:10.1016/bs.pmbts.2022.06.021

Cited by 2 publications

(1 citation statement)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGFR consists of three tyrosine kinase receptors including VEGFR-1, VEGFR-2, and VEGFR-3. VEGFR-2 is the essential receptor for the formation of the blood vasculature, whereas lymphogenesis mostly involves VEGFR-3 [ 134 – 136 ]. Thus, VEGFR is a valuable target aiming to vascular anomalies for the surface modification of NPs and widely applied in the few decades.…”

Section: Nanotechnology Applying In Therapy Of Vascular Anomaliesmentioning

confidence: 99%

Recent advances in nanomaterial-driven strategies for diagnosis and therapy of vascular anomalies

Geng,

Zou,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Nanotechnology has demonstrated immense potential in various fields, especially in biomedical field. Among these domains, the development of nanotechnology for diagnosing and treating vascular anomalies has garnered significant attention. Vascular anomalies refer to structural and functional anomalies within the vascular system, which can result in conditions such as vascular malformations and tumors. These anomalies can significantly impact the quality of life of patients and pose significant health concerns. Nanoscale contrast agents have been developed for targeted imaging of blood vessels, enabling more precise identification and characterization of vascular anomalies. These contrast agents can be designed to bind specifically to abnormal blood vessels, providing healthcare professionals with a clearer view of the affected areas. More importantly, nanotechnology also offers promising solutions for targeted therapeutic interventions. Nanoparticles can be engineered to deliver drugs directly to the site of vascular anomalies, maximizing therapeutic effects while minimizing side effects on healthy tissues. Meanwhile, by incorporating functional components into nanoparticles, such as photosensitizers, nanotechnology enables innovative treatment modalities such as photothermal therapy and photodynamic therapy. This review focuses on the applications and potential of nanotechnology in the imaging and therapy of vascular anomalies, as well as discusses the present challenges and future directions. Graphical Abstract

show abstract

Section: Nanotechnology Applying In Therapy Of Vascular Anomaliesmentioning

confidence: 99%

Recent advances in nanomaterial-driven strategies for diagnosis and therapy of vascular anomalies

Geng,

Zou,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer

Xie,

Xiao,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Genomic instability stands out as a pivotal hallmark of cancer, and PARP inhibitors (PARPi) emerging as a groundbreaking class of targeted therapy drugs meticulously crafted to inhibit the repair of DNA single-strand breaks(SSB) in tumor cells. Currently, PARPi have been approved for the treatment of ovarian cancer, pancreatic cancer, breast cancer, and prostate cancer characterized by homologous recombination(HR) repair deficiencies due to mutations in BRCA1/2 or other DNA repair associated genes and acquiring the designation of breakthrough therapy. Nonetheless, PARPi exhibit limited efficacy in the majority of HR-proficient BRCA1/2 wild-type cancers. At present, the synergistic approach of combining PARPi with agents that induce HR defects, or with chemotherapy and radiotherapy to induce substantial DNA damage, significantly enhances the efficacy of PARPi in BRCA wild-type or HR-proficient patients, supporting extension the use of PARPi in HR proficient patients. Therefore, we have summarized the effects and mechanisms of the combined use of drugs with PARPi, including the combination of PARPi with HR defect-inducing drugs such as ATRi, CHKi, HR indirectly inducing drugs like VEGFRi, CDKi, immune checkpoint inhibitors and drugs instigating DNA damage such as chemotherapy or radiotherapy. In addition, this review discusses several ongoing clinical trials aimed at analyzing the clinical application potential of these combined treatment strategies.

show abstract

VEGFR endocytosis: Implications for angiogenesis

Cited by 2 publications

References 157 publications

Recent advances in nanomaterial-driven strategies for diagnosis and therapy of vascular anomalies

Recent advances in nanomaterial-driven strategies for diagnosis and therapy of vascular anomalies

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer

Contact Info

Product

Resources

About